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In patients experiencing distributive shock, is the addition of angiotensin II 
to standard therapy more effective at stabilizing mean arterial pressure and 
decreasing mortality?
Figure 1. PRISMA Flow Diagram
INTRODUCTION
A treatment regimen for distributive shock, initially studied in the 1960s, has found new vitality 
in recent promising studies8. This research has discovered that Angiotensin II used in 
combination with vasopressors rapidly stabilizes MAP and decreases 30-day mortality rates. 
While maintaining MAP, angiotensin II can also reduce the necessary doses of vasopressors, 
thereby minimizing their dangerous side effect profile7,8,10. Thrombotic events were identified 
following the clinical use of Angiotensin II; however, this adverse side effect is well mitigated 
with VTE prophylaxis and continues to have a better side effect profile than that of vasopressors. 
Longitudinal studies are needed to assess the long-term effects of ATII as this data is currently 
unknown. It is worth considering if Angiotensin II will have further indications pending future 
investigation, such as experimenting with other forms of shock or sepsis alone.
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Year published 2014 2017 2019
Journal Critical Care New England Journal of 
Medicine
Annals of Intensive Care
Study design RCT RCT Pre-specified analysis
Sample size 20 321 patients 163 patients
Study duration 30 days 28 days 28 days
Treatment 
groups
Study Drug, n = 10
Placebo, n = 10
Standard treatment plus 
angiotensin II, n = 163
Standard treatment with 
placebo, n = 158
<5 ng/kg/min of 
angiotensin II, n = 79
>5 ng/kg/min of 
angiotensin II, n = 84
Efficacy 
outcomes
Establish dosage range 
for angiotensin II and 
determine the effect of 
the angiotensin II 
infusion on the standing 
dose of norepinephrine 
required for a MAP of 65 
mmHg
Primary - increase in MAP 
within 3 hours of initiating 
treatment
Secondary - change in 
cardiac and total 
SOFAscore
Other - all cause mortality 
at day 28
Increase in MAP within 3 
hours of initiating 
treatment, change in 
norepinephrine dose from 
baseline, and mortality on 
day 28
Results Angiotensin II group 
achieved goal MAP after 3 
hours (69.9%; P <0.001)
Cardiac SOFA scores 
improved in the 
angiotensin II group (P = 
0.01). Total SOFA score 
worsened (P = 0.49)
By day 28, 46% of the 
angiotensin II group died 
(P = 0.12)
89.9% of the <5 ng/kg/min 
group achieved goal MAP 
response by the 3rd hour, 
compared to 51.2% of the 
>5 ng/kg/min group (P 
<0.001)
At hour 48, 52% of the <5 
ng/kg/min group 
discontinued all 
vasopressors versus 30% 
of the other group
On day 28, 67% of the 
lower dose group 
remained alive and only 
41% of the higher dose 





Double-blinded with block 
randomization
Conducted studies 
internationally in 75 
different ICUs
Implemented an intention 
to treat analysis to preserve 
statistical power
Limitations
Funding by La Jolla 
Pharmaceutical 
Strengths
Strong significance with 
high P values
Limitations
Funding by La Jolla 
Pharmaceutical 
Small sample size with 
low power
Table 1. Overview of Reviewed Studies and Results
Figure 2. Kaplan-Meier Plot of Survival Over 28 Days6 – Angiotensin II shows 
improvement in all cause mortality on day 28.
• Distributive shock is the most common category of shock and poses an 
extensive challenge to healthcare providers1.
• The goal of all treatment in patients with distributive shock is to restore a 
mean arterial pressure (MAP) at or above 65 mmHg2.
• Current guidelines recommend vasopressors in septic shock treatment. 
However, vasopressors are limited to patients in extremis (nearing 
death)2 because they are found to induce immunosuppression and cause 
cardiac toxicity, heart failure, and mesenteric ischemia3.
• Synthetic Angiotensin II is a newly suggested pharmacologic therapy for 
distributive shock due to the multiple endogenous hormonal pathways by 
which it elevates blood pressure and its limited side effect profile.
